Hoyam calls FTC lawsuit nothingburger, sees buying opportunity as Hims & Hers disrupts pharma
The FTC lawsuit is a sign Hims & Hers is winning as the front door to healthcare, terrifying Big Pharma; any fines are immaterial relative to revenue and subscriber growth traject…